| CEO Name | Marc Dunoyer |
| Nationality | France |
| Net Worth Estimation | $40 million |
Marc Dunoyer's estimated net worth of around $40 million comes from his executive compensation, stock awards, and long-standing leadership roles at major pharmaceutical firms like Alexion Pharmaceuticals, Inc. and AstraZeneca. His financial profile includes salary, bonuses, equity grants, and accumulated stock holdings resulting from his tenure as CEO and executive director.
Marc Dunoyer, CEO of Alexion Pharmaceuticals, Inc., has an estimated net worth of $40,000,000, which is 8% of the maximum and 40% of the minimum net worth in the pharmaceutical business category. His net worth places him well above the minimum threshold for CEOs in this sector.
Business Category: Pharmaceutical
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 500000000 USD
Marc Dunoyer Performance in Alexion Pharmaceuticals, Inc.
Marc Dunoyer, CEO of Alexion Pharmaceuticals, leads with a strategic focus on innovation and patient-centric solutions. His decisive leadership accelerated pipeline development and strengthened global market expansion. Under Dunoyer's tenure, Alexion has enhanced operational performance, driving revenue growth and solidifying its position in rare disease therapies.
Latest News
Alexion Pharmaceuticals Leadership Changes Amid Investigation
Alexion Pharmaceuticals saw its CEO and CFO depart amid an investigation into sales practices for its main drug, Soliris, with former AstraZeneca CEO David Brennan appointed interim CEO. This leadership shake-up caused a stock drop and raised concerns during the ongoing internal probe.
Source: http://www.biopharmadive.com/news/alexion-ceo-cfo-out-amid-soliris-investigation/432177/